RedHill Biopharma Announces Positive TopLine Results from Phase II Study of BEKINDAÂ in Patients with DiarrheaPredominant Irritable Bowel Syndrome IBSD

BEKINDAÂiÂ12 mg Phase II study successfully met its primary endpoint improving primary efficacy outcome of stool consistency by an absolute difference of 19.4 vs. placebo and comparing favorably with previously reported outcomes from studies of Xifaxan...